The attributable fraction (AF) is a widely used measure to assess the impact of an exposure on a disease. It is commonly estimated through maximum likelihood, which requires a regression model for the outcome. Recently, it was demonstrated that the AF can also be estimated through inverse probability weighting, which requires a model for the exposure. In this paper, we derive doubly robust estimators for the AF. These estimators require one model for the outcome and one model for the exposure and are consistent if either model is correct, not necessarily both. We consider both cohort/cross-sectional studies and case-control studies.
INTRODUCTION
In epidemiology, the attributable fraction (AF; a.k.a. attributable risk, Benichou, 2005 and excess fraction, Rothman and others, 2008 ) is a widely used measure to assess the impact of an exposure on a disease. It was introduced by Levin (1953) and is defined as the fraction of disease events that would be eliminated if the exposure was eliminated. Consistent estimation of AF in observational studies typically involves confounding adjustment (Benichou, 2005) . Broadly, 3 methods for adjustment have been proposed in the literature; the Mantel-Haenzel (MH) method, the weighted-sum (WS) method, and the maximum likelihood (ML) method. The MH method is fairly ad hoc and relies on an assumption of constant effects across levels of covariates. The WS method does not rely on any specific assumptions but may yield unstable estimates for high-dimensional/continuous covariates. The ML method is a general and flexible compromise, which relies on a regression model for the outcome. When the mechanisms that bring about the outcome are well understood, the outcome is a natural target for regression models. In some scenarios, however, the researcher may have a better understanding of the exposure mechanisms. This would, for example, be the case when the exposure is a treatment or a medical drug, which are often assigned to patients according to where Pr(Y = 1) is the disease prevalence and Pr(Y 0 = 1) is the exposure-free prevalence, that is, "the hypothetical probability of disease in the same population but with all exposure eliminated." We note that Benichou (2005) used the term "attributable risk" and a slightly different notation. Because Pr(Y 0 = 1) corresponds to a hypothetical scenario, it is not directly observable. Naively, we may use the disease prevalence among those who are factually unexposed, Pr(Y = 1|A = 0), as a proxy for Pr(Y 0 = 1); we denote the resulting proxy for AF with AF naive . As noted by Benichou (2005) and many others, AF naive will in general differ from AF whenever the exposure-disease relationship is confounded. The idea underlying the ML method is to "adjust" for measured confounders L, through standardization. This means that we use E{Pr(Y = 1|A = 0, L)} as a proxy for Pr(Y 0 = 1); we thus obtain a proxy for AF as
Whether the expressions in (2.1) and (2.2) are equal or not, depends on whether all relevant confounders are included in L. The problem of selecting confounders to adjust for is important and nontrivial (e.g. Pearl, 2000) . This problem, however, is beyond the scope of this paper. We will throughout assume that a vector of relevant confounders L have been measured, and we will develop inference for the expression in (2.2). For simplicity, we will from now on refer to E{Pr(Y = 1|A = 0, L)} as the exposure-free prevalence, and to the expression in (2.2) as the AF. We use p and p 0 to abbreviate Pr(Y = 1) and
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COHORT/CROSS-SECTIONAL STUDIES
In this section, we assume that the observed data consists of n i.i.d. observations from the joint distribution Pr (Y, A, L) . This sampling scheme is usually referred to as a cross-sectional study. However, it may also correspond to a cohort study, where A and L are measured at baseline, and we define Y = 1 for subjects who develop the disease before end of follow up. We briefly review the ML estimator and the IPW estimator in Section 3.1 and derive a DR estimator in Section 3.2.
ML and IPW
In both these methods, AF is estimated by replacing p and p 0 in (2.2) with consistent estimates thereof. In both methods, the sample disease prevalence is used as an estimate of the population prevalence;
The methods differ, however, in how p 0 is estimated. In the ML method, a parametric model for Pr(Y |A = 0, L), say Pr(Y |A = 0, L; β), is fitted by solving the ML score equation for β (see Section 1 in the Supplementary Material available at Biostatistics online for a comment on model choice); we useβ to denote the solution. p 0 is estimated by averaging the fitted model over the sample distribution of
In the IPW method, a parametric model for Pr(A|L), say Pr(A|L; α), is fitted by solving the ML score equation for α; we useα to denote the solution. A "pseudo sample" is obtained by assigning a weight, Pr −1 (A i |L i ;α), to each subject. p 0 is estimated as the disease prevalence among the unexposed in the pseudo sample;
, where 1(•) equals 1 if • is true and equals 0 otherwise. We useÂF ML andÂF IPW to denote the ML estimator and the IPW estimator of AF, respectively. The asymptotic distributions ofÂF ML andÂF IPW can be obtained through the delta method (Greenland and Drescher, 1993; Sjölander, 2010) .
DR estimation
To construct the DR estimator for AF, we define
where E(•| A, L; β) and E(•|L; α) are expectations under the models Pr(Y |A = 0, L; β) and Pr(A|L; α), respectively. For fixed values (α, β), we may estimate p 0 by solving the equation
for p 0 ; we denote this estimator withp 0 (α, β). It follows from a more general result in Robins (1999) , that
is DR in the sense that it is consistent if either model is correct. In practice, we replace the fixed values (α, β) in (3.1) by the ML estimates (α,β). It can be shown thatp 0 (α,β) is DR as well.p 0 (α,β) can be expressed analytically aŝ
We obtain the DR estimator for AF by replacing p 0 and p in (2.2) byp 0 (α,β) andp, respectively; we denote this estimator withÂF DR,CS . In Section 3 of the Supplementary Material available at Biostatistics online, we derive the asymptotic distribution ofÂF DR,CS .
CASE-CONTROL STUDIES
Frequently, data are collected according to a case-control sampling scheme. Under this scheme, data consist of n 1 i.i.d. observations from Pr(A, L|Y = 1) (the cases) and n 0 i.i.d. observations from Pr(A, L|Y = 0) (the controls). We define n = n 1 + n 0 . In general, AF cannot be consistently estimated from case-control data. This is because AF involves the disease prevalence p, which is not identifiable in case-control studies. An important special case occurs when the disease is rare. For this case, an approximate ML estimator for AF (Miettinen, 1974; Bruzzi and others, 1985) can be constructed. We briefly review the approximate ML estimator in Section 4.1, and derive a DR estimator in Section 4.2. In Section 4 of the Supplementary Material available at Biostatistics online, we discuss how to adapt the DR estimation procedure for matched case-control studies.
Approximate ML
Miettinen (1974) and Bruzzi and others (1985) noted that when the disase is rare (i.e.
, AF may be approximated by
where
is the conditional (on L) odds ratio for Y and A. Thus, when the disease is rare, an approximately consistent estimator for AF may be obtained through the following steps. First, a logistic regression model is specified for Pr(Y |A, L). Any such model can be decomposed into 2 parts; one model for log{OR(L)}, say log{OR(L; ψ)}, and one model for logit{Pr
we denote the solution with (φ,ψ PRO ). It is well known thatψ PRO , but notφ, is consistent under case-control sampling (Prentice and Pyke, 1979) . Finally, the estimator of AF is constructed by replacing OR(L) in (4.1) with OR(L;ψ PRO ), and averaging over the sample distribution of ( A, L) for the cases; we denote this estimator withÂF PRO . The asymptotic distribution ofÂF PRO can be obtained through the delta method (Greenland and Drescher, 1993) .
Before we derive the DR estimator, we note that an approximate ML estimator can also be based on the "retrospective" likelihood. This estimator is constructed by specifying one model for log{OR(L)}, say log{OR(L; ψ)}, and one model for logit{Pr(A = 1|Y = 0, L)}, say logit{Pr(A = 1|Y = 0, L; λ)}. These models together define a logistic model for Pr(A|Y, L). (λ, ψ) are estimated by solving the "retrospective" score equation,
we denote the solution with (λ,ψ RET ). Finally, an estimator for AF is obtained by replacing OR(L) in (4.1) with OR(L;ψ RET ) and averaging over the sample distribution of (A, L) for the cases; we denote this estimator withÂF RET .
DR estimation
For fixed values (φ, λ), we may estimate ψ by solving the equation
for ψ; we denote this estimator withψ(φ, λ). Tchetgen Tchetgen and Rotnitzky (2009) 
is DR in the sense that it is consistent if either model is correct. In practice, we replace the fixed values (φ, λ) in (4.2) by the ML estimatesφ 0 andλ 0 , obtained by solving the score equations
; λ)} = 0 for φ and λ, respectively. It can be shown thatψ(φ 0 ,λ 0 ) is DR as well. We obtain the DR estimator for AF by replacing OR(L) in (4.1) with OR{L;ψ(φ 0 ,λ 0 )} and averaging over the sample distribution of (A, L) for the cases; we denote this estimator withÂF DR,CC . In Section 3 of the Supplementary Material available at Biostatistics online, we derive the asymptotic distribution ofÂF DR,CC .
SIMULATIONS
To investigate the performance ofÂF DR,CS , we generated 10 000 samples, of n = 1, 000 i.i.d. observations, from the joint model
with α 0 = 2.1, α 1 = α 2 = 1.02, α 3 = −1.6, β 0 = −2.3, β 1 = β 2 = −1.02, β 3 = 1.6, and β 4 = 1.27. These models were chosen in line with the data analysis in Section 6.1. For these models and parameter values, we have that Pr(Y = 1) = Pr(A = 1) = 0.1 and AF = 0.2. Furthermore, AF naive equals 0.3, which represents quite severe confounding. Each sample was analyzed 4 times. First, with both models for Pr(A|L) and Pr(Y |A = 0, L) correctly specified. Second, with Pr(A|L) correct but the incorrectly specified model logit{Pr(
Third, with Pr(Y |A = 0, L) correct but the incorrectly specified model logit{Pr(A = 0|L)} = α 0 + α 1 L 1 + α 2 L 2 . Fourth, with both models incorrect. For each sample and analysis method, we calculatedÂF ML ,ÂF IPW , andÂF DR,CS . For each analysis method, we calculated the mean (over the 10 000 samples) estimates, the mean theoretical standard errors (se) obtained from the delta method/sandwich formula, the empirical standard errors, and the empirical coverage probabilities of the corresponding 95% Wald confidence intervals. We considered 2 confidence intervals; the untransformed intervalÂF ± 1.96se, and the transformed log(1−ÂF) interval 1−(1−ÂF)exp{±1.96se/(1−ÂF)} proposed by Greenland and Drescher (1993) . Table 1 shows the results. All 3 estimators work well under correct model specifications. The mean estimates are close to the true AF, the mean theoretical standard errors are close to the mean empirical standard errors, and the coverage probabilities of the confidence intervals are very close to the nominal level of 95%. When the model for Pr(Y |A = 0, L) is misspecified, AF ML is severely biased. Similarly, when the model for Pr(A|L) is misspecified,ÂF IPW is severely biased. As the theory predicts however,ÂF DR,CS works well even if either of these models are misspecified. The differences in empirical standard error for the 3 estimators are minor.
To investigate the performance ofÂF DR,CC , we generated 10 000 samples, of n 1 = 500 cases and n 0 = 500 controls, from the joint model with λ 0 = −3, λ 1 = λ 2 = 0.9, λ 3 = −1.8, φ 0 = −5.7, φ 1 = φ 2 = 0.9, and φ 3 = −1.8. For these models and parameter values, we have that Pr(Y = 1) = 0.01 (rare disease), Pr(A = 1) = 0.1 and AF = 0.2, and AF naive = 0.3. Each sample was analyzed 4 times. First, with both models for Pr(A|Y = 0, L) and Pr(Y |A = 0, L) correctly specified. Second, with Pr(A|Y = 0, L) correct but the incorrectly specified model logit{Pr
Fourth, with both models incorrect. For each sample and analysis method, we calculatedÂF PRO ,ÂF RET , andÂF DR,CC . For each analysis method, we calculated the same summary statistics as for the cohort/cross-sectional simulations above. Table 2 shows the results. The pattern is very similar to the pattern we observed in the cohort/cross-sectional simulations.ÂF PRO andÂF RET work well if their corresponding models are correctly specified but are otherwise severely biased.ÂF DR,CC works well even if one of the 2 models are misspecified. Under the scenarios for which the estimators are consistent, respectively, the differences in their empirical standard errors are minor. We note that even under correct model specification, all 3 estimates have a bias of ≈ 5%. This bias persists even with larger samples (results not shown) and is most likely due to the odds ratio approximation of the relative risk in (4.1).
PRACTICAL EXAMPLES

Fraction of cardiovascular disease attributable to abnormal weight
Sjölander (2010) used data from the National March Cohort (NMC) (Lagerros, 2006) to estimate the fraction of cardiovascular disease (CVD) cases during a 10-year period, which could be attributed to abnormal weight. The NMC was established in 1997, when 300 000 Swedes participated in a national fund-raising event organized by the Swedish Cancer Society. Every participant was asked to fill out a questionnaire that included items on known or suspected risk factors for CVD. Questionnaire data were obtained on over 43 880 individuals. For each of these 43 880 subjects, body mass index (BMI) was recorded at baseline. Using the Swedish patient registry, the NMC participants have been followed until 2006 and each CVD event recorded. Sjölander defined Y = 1 if a subject developed CVD before end of follow up Y = 0 otherwise. He further defined A = 0 for those subjects with baseline BMI between 18.5 and 25. This range is considered as normal weight by the WHO (1995) . It is typically used as the exposure reference level in the literature on AFs for CVD and related diseases (e.g. Meigs and others (2006); Flegal and others (2005) ), however sometimes including levels below 18.5 as well. With these definitions, AF is the fraction of CVD events that would have been prevented in the NMC during follow up, had all participants had normal weight. Based on self-reported history of physical activity (pa), Sjölander constructed a continuous measure ranging from 0 (minimal level of activity) to 100 (maximal level). He let L consist of age at baseline and the constructed measure of pa. Based on the outcome model logit{Pr(Y = 1| A = 0, L)} = β 0 + β 1 age + β 2 pa, Sjölander obtainedÂF ML = 0.12(0.08, 0.15); the number in brackets representing the lower and upper 95% confidence limits, respectively. Based on the exposure model logit{Pr(A = 0|L)} = α 0 + α 1 age + α 2 pa, he obtainedÂF IPW = 0.05(0.01, 0.08). Before proceeding, we remind the reader that although we focus on the expression in (2.2), we ultimately wish to make inference on the "true" AF, as defined in (2.1). In the example by Sjölander (2010) , there are most likely unmeasured confounders which have not been adjusted for example, sex, race, etc. If the influence of these confounders is strong, then any method we use may be severely biased in estimating (2.1), regardless of its precision in estimating (2.2). The 2 estimation methods gave very different results;ÂF ML is almost twice as large asÂF IPW . This indicates that at least one of the models was severely misspecified. Using the same models, we calculatedÂF DR,CS from the NMC data, obtainingÂF DR,CS = 0.12(0.08, 0.15). The similarity betweenÂF ML andÂF DR,CS , together with their dissimilarity withÂF IPW , indicates that misspecification is most severe in the exposure model. We made an attempt to improve the exposure model by extending it to logit{Pr(A = 0|L)} = α 0 + α 1 age + α 2 pa + α 3 age 2 + α 4 pa 2 + α 5 age × pa. We found that (α 3 ,α 4 ,α 5 ) were all significant, at 5% significance level. Using the refined exposure model, we obtained AF IPW = 0.10(0.07, 0.14), which is closer toÂF ML andÂF DR,CS . Subsequently, we refined the outcome model in a similar fashion; logit{Pr(Y = 1| A = 0, L)} = β 0 +β 1 age+β 2 pa+β 3 age 2 +β 4 pa 2 +β 5 age×pa. Of (β 3 ,β 4 ,β 5 ), onlyβ 3 was significant, at 5% significance level. Under the refined outcome model, we obtainedÂF ML = 0.11(0.07, 0.14), which is quite close to the corresponding estimate from the simpler model. Taken together, these findings strongly suggest that misspecification was indeed most severe in the exposure model.
The example demonstrates that the DR estimator makes a valuable compromise between the exposure model and the outcome model. Thus, the DR estimator may serve as a useful complement to a model fit assessment. We note though, that the DR estimator only acknowledges a bad model fit to the extent that it induces bias in the target parameter. In this sense, the DR estimator offers a more "targeted" approach to model fit assessments than standard methods (e.g. residual analysis).
When L is low dimensional, as in this example, it is relatively straightforward to carry out model fit assessments and to improve on badly misspecified models. In many scenarios, however, we may wish to adjust for a high-dimensional vector of potential confounders. When L is high dimensional, the power to detect model misspecifications is limited, and the set of competing models may be large. Thus, for these scenarios, DR estimators are very attractive. In our second example (Section 6.2), we consider such a scenario.
6.2 Fraction of lung cancer and coronary heart disease attributable to smoking Johnson and others (2003) used data from the National Medical Expenditure Survey (NMES) to estimate the fraction of disease cases in the US population during 1987, which could be attributed to smoking, for 2 broadly defined disease groups. The first group, LC, included lung and laryngeal cancer, and the second group, CHD, included coronary heart disease and stroke. The 1987 NMES data included information on medical conditions as well as various personal characteristics for 38 446 subjects, selected to represent the U.S. civilian, noninstitutionalized population. From this cohort, a subset of 13 505 subjects was selected (Johnson and others, 2003) . Exposure (i.e. smoking) levels were ascertained through the Adult Self-Administered Questionnaire Houshold Survey. After exclusion of all subjects with missing data, 10 479 subjects remained. Johnson and others used ML to estimate the AFs of LC and CHD, based on the logistic regression model logit{Pr race, pov, marital, edu, belt, reg) , with Y being an indicator of LC/CHD, f 1 (A) being a nonlinear function of dose (i.e. present and past smoking levels) and pov, marital, edu, belt, and reg, representing income levels, marital status, education level, seatbelt use, and census regions, respectively. For a more detailed explanation of these variables we refer to Johnson and others (2003) . They obtained estimateŝ AF ML = 0.70(0.60, 0.90) for LC andÂF ML = 0.20(0.13, 0.26) for CHD. We reanalyzed the NMES data using the models logit{Pr(Y = 1|A = 0, L)} = β 0 +β f 2 (L) and logit{Pr(A = 0|L)} = α 0 +α f 2 (L). We obtained estimatesÂF ML = 0.73(0.62, 0.84),ÂF IPW = 0.73(0.61, 0.84),ÂF DR,CS = 0.73(0.62, 0.84) for LC andÂF ML = 0.18(0.12, 0.25),ÂF IPW = 0.15(0.09, 0.22),ÂF DR,CS = 0.18(0.11, 0.24) for CHD. For LC, the estimates are practically identical. This coherence suggests that for LC none of the models is so severely misspecified to cause a bias in the estimates. For CHD,ÂF ML is slightly bigger thanÂF IPW . Because of the large parameter space, it is not straightforward to locate any misspecification and to make improvements. However, we observe thatÂF DR,CS is virtually identical toÂF ML .
DISCUSSION
In this paper, we have developed DR estimators for the AF, for both cohort/cross-sectional studies and case-control studies. These estimators require 2 regression models and are consistent if either model is correct, not necessarily both. In our simulated scenarios, the DR estimators were almost as efficient as the estimators previously proposed in the literature, which use only one regression model. Furthermore, in our simulated scenarios, the estimators which use only one regression model were severely biased, whenever the model was incorrectly specified. These results speak in favor of the DR estimators.
In practice, it is unlikely for any model to be exactly correct. Several authors have investigated the performance of DR estimators in various contexts when both working models are misspecified (Bang and Robins, 2005; Davidian and others, 2005; Kang and Schafer, 2007) . These authors have drawn somewhat different conclusions. Bang and Robins (2005) state: "In our opinion, a DR estimator has the following advantage that argues for its routine use: if either the [outcome] model or the [exposure] model is nearly correct, then the bias of a DR estimator . . . will be small." In contrast, Kang and Schafer (2007) provided a simulated example where DR estimators were outperformed by IPW and ML estimators, all involved models being moderately misspecified. They concluded: ". . . two wrong models are not necessarily better than one." Several authors have proposed modifications of DR estimators, to increase their performance. In somewhat different contexts, Tan (2006) and Cao and others (2009) showed how to obtain DR estimators which have a guaranteed efficiency improvement relative to the IPW estimator, even under model misspecification. Vansteelandt and others (2010) showed that by fitting the working models in a particular way, one may obtain a DR estimator which is consistent even when both working models are incorrect. Whether these ideas can be adapted to the DR estimators presented in this paper is a topic of future research.
